2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-110019
    Indatraline hydrochloride 96850-13-4 98%
    Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis.
    Indatraline hydrochloride
  • HY-110050
    GP1a 511532-96-0 99.66%
    GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.
    GP1a
  • HY-110097
    Aptiganel hydrochloride 137160-11-3 99.80%
    Aptiganel hydrochloride (Cerestat) is a non-competitive NMDA receptor antagonist with neuroprotective effect.
    Aptiganel hydrochloride
  • HY-110152
    LSN2463359 1401031-52-4 98.49%
    LSN2463359 is positive allosteric modulator of metabotropic glutamate 5 (mGlu5). LSN2463359 attenuates aspects of the behavioral response to administration of the competitive NMDA receptor antagonist. LSN2463359 selectively attenuates reversal learning deficits observed in the neurodevelopmental MAM E17 model. LSN2463359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LSN2463359
  • HY-110157
    AC-186 1421854-16-1 99.61%
    AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender selective neuroprotective effects in a male rat model of Parkinson's disease.
    AC-186
  • HY-110184
    PK-THPP 1332454-07-5 ≥99.0%
    PK-THPP is a potent and brain-penetrant TWIK-related acid-sensitive K+ ion channel (K2P9.1 or TASK-3) blocker with IC50s of 35 nM and 300 nM for TASK-3 and TASK-1, respectively. PK-THPP shows no or less activity against other K+ channels. PK-THPP is an effective breathing stimulant and can be used for the study of breathing disorders.
    PK-THPP
  • HY-110241
    Dianicline dihydrochloride 292634-27-6 99.97%
    Dianicline dihydrochloride is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of agents that includes varenicline and cytisine for smoking cessation. Dianicline dihydrochloride increases cessation rates in a dose-dependent manner.
    Dianicline dihydrochloride
  • HY-110255
    AZD 2066 934282-55-0 ≥99.0%
    AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease.
    AZD 2066
  • HY-111055
    BIP-135 941575-71-9 99.86%
    BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.
    BIP-135
  • HY-111527
    PPZ2 896203-18-2 99.92%
    PPZ2 is a diacylglycerol (DAG)-activated TRPC3/TRPC6/TRPC7 channel activator with activity in promoting neuronal development and survival. PPZ2 activates recombinant TRPC3/TRPC6/TRPC7 channels in a dose-dependent manner without affecting other TRPC channels. PPZ2 elicits cation currents and calcium ion (Ca(2+)) influx in cultured central neurons. PPZ2 is able to induce BDNF-like neurite outgrowth and neuroprotection, an effect that disappears after TRPC3/TRPC6/TRPC7 knockdown or inhibition. PPZ2 also increases the activation of the calcium-dependent transcription factor cAMP response element binding protein. The effects of PPZ2 suggest that calcium signaling mediated by activation of DAG-activated TRPC channels plays an important role in its neurotrophic effects.
    PPZ2
  • HY-111954
    (+)-Erinacin A 156101-08-5 99.97%
    (+)-Erinacin A (Erinacine A) is a cyanoditerpenoid isolated from Hericium erinaceus with anticancer, anti-inflammatory and neuroprotective activities. (+)-Erinacin A can induce cancer cell death by activating extrinsic and intrinsic apoptosis pathways. (+)-Erinacin A can also inhibit the expression of NO synthase (iNOS) and the production of nitrotyrosine to exert inflammatory and neuroprotective effects, thereby reducing ischemic brain damage.
    (+)-Erinacin A
  • HY-112555
    PDE7-IN-2 107522-19-0 ≥99.0%
    PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC50 value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease.
    PDE7-IN-2
  • HY-113053
    Prostaglandin A1 14152-28-4 98%
    Prostaglandin A1 is a dehydration derivate of Prostaglandin E1. Prostaglandin A1 exhibits inhibitory activities against tumor growth, inflammation, virus replication, platelet aggregation and excitotoxin-induced neurons apoptosis.
    Prostaglandin A1
  • HY-113689
    GAT211 102704-40-5 ≥99.0%
    GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC50 values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research.
    GAT211
  • HY-113845
    (+)-Intermedine 10285-06-0 ≥99.0%
    (+)-Intermedine, a pyrrolizidine alkaloid (PA), exhibits significant cytotoxicity in neural progenitor cells (NPCs).
    (+)-Intermedine
  • HY-114146
    CID 1375606 313493-80-0 99.90%
    CID 1375606 is a surrogate agonist of orphan G protein-coupled receptor GPR27.
    CID 1375606
  • HY-114520
    TT01001 1022367-69-6 99.38%
    TT01001 is a potent and orally active mitoNEET ligand. TT01001 reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 improves type II diabetes without causing weight gain.
    TT01001
  • HY-114615
    AMP-Deoxynojirimycin 216758-20-2 99.7%
    AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor.
    AMP-Deoxynojirimycin
  • HY-114978
    VU0424465 1428630-85-6 99.84%
    VU0424465 is a potent and partial PAM (positive allosteric modulator)-agonist for mGlu5 mediated iCa2+ mobilization. VU0424465 exhibits high affinity at MPEP allosteric binding site, with a Ki value of 11.8 nM. VU0424465 is also a agonist for pERK1/2 in cortical neurons.
    VU0424465
  • HY-116171
    (Rac)-Calpain Inhibitor XII 181769-57-3
    (Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of calpain I (μ-calpain, Ki=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, Ki=120 nM) and cathepsin B (Ki=750 nM). (Rac)-Calpain Inhibitor XII has the potential for studying the role of calpains in diverse processes, including neutrophil chemotaxis, neuronal signaling, and cardiac response to injury.
    (Rac)-Calpain Inhibitor XII
Cat. No. Product Name / Synonyms Application Reactivity